Advertisement

Topics

Ipsat Therapies Oy Company Profile

23:01 EDT 20th June 2018 | BioPortfolio

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance

Location

Helsinki Business and Science Park
Viikinkaari 4
Helsinki
FI-00790
Finland

Contact

Phone: 358 9 3193 6500
Fax: 358 9 3193 6519
Email: info@ipsat-ther.com


News Articles [179 Associated News Articles listed on BioPortfolio]

Opportunity remains in oncology for gene therapies, says GlobalData

Small pharma leads the way in cancer gene therapies Gene therapies combine reduced treatment duration with a higher chance of...Read More... The post Opportunity remains in oncology for gene therapies...

Gene Therapies are Proving their Worth, but with Million Dollar Price Tags, it’s not Clear Who should Pay for Them

Sterghios Moschos, Associate Professor in Cellular and Molecular Sciences at Northumbria University discusses the benefits of gene therapies and the financial implications of treatments. If you were b...

In a bid to promote stem cell therapies, health officials open a new door for promising contenders

At a time when there’s significant hype around stem cell therapies, the FDA is moving to promote therapies that show the greatest potential.

FDA Sets Path for Stem Cell Therapies

(CNN) – Just months after the US Food and Drug Administration announced efforts to crack down on stem cell clinics touting unapproved therapies, the agency now plans to help expedite the develop...

Nonstatin therapies aid in additional LDL lowering

LAS VEGAS — Nonstatin therapies such as ezetimibe and PCSK9 inhibitors reduce the risk for CVD in patients who require additional LDL lowering, according to a presentation at the National Lipid Asso...

SMC endorses five new therapies for NHS Scotland

Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.

Product characterisation key to successful CAR T therapies, Autolus

CAR T-cell understanding must come before the process design if such therapies are ever going to be accessible to a larger patient population, says Autolus.

ApolloBio picks up I/O therapies for China market

Rising cancer rates in China have drawn the attention of drugmakers, spurring increased R&D for therapies designed for Chinese patients. 

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Hepsera [Excella GmbH]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Hepsera [Gilead Sciences, Inc.]

These highlights do not include all the information needed to use HEPSERA safely and effectively. See full prescribing information for HEPSERA. HEPSERA (adefovir dipivoxil) tablet for oral use Initia...

Olay total effects uv moisturizer [Procter & Gamble Manufacturing Company]

OLAY total effects

PubMed Articles [526 Associated PubMed Articles listed on BioPortfolio]

Efficacy of Pain Relief in Different Postherpetic Neuralgia Therapies: A Network Meta-Analysis.

Postherpetic neuralgia (PHN) is a nerve pain disease usually controlled by different therapies, i.e., topical therapies, antiepileptics, analgesics, antipsychotics, antidepressants, anti-dementia drug...

A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis.

Systemic immunomodulatory therapies are the principal means of managing non-infectious uveitis. This review aims to explore the current landscape of systemic uveitis treatments, including biologic the...

Funding breakthrough therapies: A systematic review and recommendation.

Advanced therapy medicinal products (ATMPs) are innovative therapies likely associated with high prices. Payers need guidance to create a balance between ensuring patient access to breakthrough therap...

Advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies.

The efficacy and safety of non-pharmacological therapies for the treatment of acne vulgaris: A systematic review and best-evidence synthesis.

Acne vulgaris is a multifaceted skin disorder, affecting more than 85% of young individuals worldwide. Pharmacological therapy is not always desirable because of the development of antibiotic resistan...

Clinical Trials [1506 Associated Clinical Trials listed on BioPortfolio]

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

The proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (CAM) therapies to understand the selection of patients and CAM ther...

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for wh...

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment wi...

Intensive Therapies in Children With Hemiplegia

This is a comparative study where two protocols of intensive therapies will be applied to study the improvements in the functional performance of the affected upper limb of children with h...

Dysphagia After Different Swallowing Therapies

Dysphagia after stroke is associated to increased pulmonary complications and mortality. The swallowing therapies could decrease the pulmonary complications and improve the quality of life...

Companies [839 Associated Companies listed on BioPortfolio]

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospita...

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

MolMed S.p.A.

Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is an integrated company covering all functions, from di...

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including: ...

Accent Therapeutics

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompa...

More Information about "Ipsat Therapies Oy" on BioPortfolio

We have published hundreds of Ipsat Therapies Oy news stories on BioPortfolio along with dozens of Ipsat Therapies Oy Clinical Trials and PubMed Articles about Ipsat Therapies Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsat Therapies Oy Companies in our database. You can also find out about relevant Ipsat Therapies Oy Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...


Corporate Database Quicklinks



Searches Linking to this Company Record